Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Valion Bio (TIVC) Shares Outstanding (Weighted Average) (2021 - 2025)

Valion Bio has reported Shares Outstanding (Weighted Average) over the past 5 years, most recently at $8.5 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 2862.57% year-over-year to $8.5 million; the TTM value through Dec 2025 reached $8.5 million, up 2862.57%, while the annual FY2025 figure was $8.5 million, 2862.57% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $8.5 million at Valion Bio, up from $1.3 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $9.7 million in Q1 2022 and troughed at $46650.0 in Q4 2023.
  • A 5-year average of $2.2 million and a median of $667993.0 in 2025 define the central range for Shares Outstanding (Weighted Average).
  • Biggest five-year swings in Shares Outstanding (Weighted Average): plummeted 97.93% in 2023 and later soared 2862.57% in 2025.
  • Year by year, Shares Outstanding (Weighted Average) stood at $3.5 million in 2021, then plummeted by 97.23% to $96778.0 in 2022, then crashed by 51.8% to $46650.0 in 2023, then surged by 516.01% to $287370.0 in 2024, then soared by 2862.57% to $8.5 million in 2025.
  • Business Quant data shows Shares Outstanding (Weighted Average) for TIVC at $8.5 million in Q4 2025, $1.3 million in Q3 2025, and $739618.0 in Q2 2025.